Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been given a consensus rating of “Moderate Buy” by the six analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $10.80.

Several research firms recently commented on RGLS. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. Finally, StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after acquiring an additional 453,784 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after purchasing an additional 37,480 shares in the last quarter. Creative Planning bought a new position in shares of Regulus Therapeutics in the third quarter valued at approximately $26,000. Finally, Rhumbline Advisers bought a new position in shares of Regulus Therapeutics in the second quarter valued at approximately $136,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Trading Down 1.8 %

NASDAQ RGLS opened at $1.61 on Friday. The business’s 50-day moving average price is $1.52 and its two-hundred day moving average price is $1.74. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79. The firm has a market capitalization of $105.46 million, a PE ratio of -1.50 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.